The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens are seeking approval to list the treatments on the Australian Pharmaceutical Benefits Scheme (PBS).
Read More
Combination drug therapy demonstrates potential to treat AMD subtype
Data from patients with a subtype of AMD enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ranibizumab (Lucentis), compared to ranibizumab alone, have been presented virtually at a conference in Miami.
Read More
Read More
Study: Third of nAMD patients safely stopped eye injections
A new study has shown up to a third of neovascular age-related macular degeneration (nAMD) patients may safely be able to stop intravitreal injections after a year, while also highlighting a potential biomarker to identify the best candidates.
Read More
Read More
Artificial intelligence: eyecare’s friend of foe?
Eyetelligence is a new Australian-developed AI system helping clinicians screen for three types of eye disease. PROFESSOR MING HE – the clinical expert behind the software – discusses why optometrists should embrace the technology and its potential in other health fields.
Read More
Annual out-of-pocket eye injection costs to double to $3,900 under rebate cut – modelling
Prominent Australian Ms Ita Buttrose has used a National Press Club address to reveal alarming new data showing that 47,000 more Australians will experience severe vision loss or blindness if a Medicare rebate cut for intravitreal injections is given the green light.
Read More
Read More
Novartis secures PBS recommendation for Beovu
An independent expert panel has recommended Novartis’ treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD) patients as a second-line anti-VEGF treatment.
Read More
Read More
Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange
Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ahead of pivotal Phase 3 trials of its lead drug candidate.
Read More
Read More
Opthea meets US and European regulators over Phase 3 trial
A Melbourne-based drug company is one step closer to starting Phase 3 clinical trials and pre-commercial development of its novel treatment for neovascular age-related macular degeneration (nAMD).
Read More
Read More
Tackling treatment adherence in AMD
As part of Macula Month this May, Insight explores why treatment adherence remains such a major challenge for some patients and how the sector is working to overcome it.
Read More
Read More
Opthea progresses DME trials despite COVID-19 disruption
Results are imminent in biopharmaceutical company Opthea’s latest clinical trial evaluating the safety and efficacy of its lead drug candidate with Eylea in diabetic macular edema (DME) patients.
Read More
Read More